Sunday 18 October 2026
Export BDTX’s income statement to Excel — free account
Black Diamond Therapeutics, Inc.
BDTX Healthcare Biotechnology
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million. In the quarter to June 2026, EPS grew 10.5% and free cash flow grew 12.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.72
0.02
−1.15%
Follow BDTX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | — | 6.23 |
Altman Z-Score |
— | — | — | — | — | — | — | — | (0.10) |
P/S ratio |
— | — | — | — | — | — | — | — | 0.00 |
P/FCF ratio |
— | — | — | — | — | — | — | — | 4.66 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | — | — | (0.83) |
P/Operating CF |
— | — | — | — | — | — | — | — | (20.36) |
P/B ratio |
— | — | — | — | — | — | — | — | 1.23 |
Price to Tangible BV |
— | — | — | — | — | — | — | — | 1.23 |
EV/Sales |
— | — | — | — | — | — | — | — | 0.00 |
EV/EBITDA |
— | — | — | — | — | — | — | — | 0.74 |
EV/Operating CF |
— | — | — | — | — | — | — | — | 0.32 |
EV/FCF |
— | — | — | — | — | — | — | — | 0.32 |
Quick Ratio |
3.53 | 20.06 | 31.80 | 22.16 | 8.87 | 8.05 | 6.69 | 4.79 | 8.18 |
Current Ratio |
3.55 | 20.07 | 32.02 | 22.48 | 9.12 | 8.37 | 6.82 | 4.92 | 8.42 |
Net Debt/EBITDA |
(1.12) | 5.83 | 5.28 | 4.53 | 1.66 | 1.33 | 1.53 | 1.26 | (10.01) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(1.87) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 |
Operating CF/Net income |
0.51 | 0.95 | 0.70 | 0.78 | 0.80 | 0.93 | 0.81 | 0.89 | 1.32 |
Capex/Depreciation |
0.00 | (1.73) | (0.45) | (2.73) | (13.22) | (0.36) | 0.14 | 0.27 | 0.08 |
Interest Coverage |
(126.74) | (2,226.00) | — | (69,570.00) | (36.63) | (45.71) | — | — | — |
| 41.43% | 80.40% | 112.47% | (51.61%) | (49.87%) | (58.52%) | (70.94%) | (69.67%) | 22.88% | |
| (15.38%) | (34.47%) | (33.56%) | (27.57%) | (43.51%) | (45.14%) | (52.37%) | (49.55%) | 16.84% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(79.54%) | (18.14%) | (23.35%) | (22.00%) | (64.38%) | (79.26%) | (71.00%) | (84.98%) | 19.11% |
Average Days of Receivables |
— | — | — | — | — | — | — | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 47.94% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23.67% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 9.47% |
Graham Net Nets |
— | — | — | — | — | — | — | — | 0.74 |
Graham Number |
— | — | — | — | — | — | — | — | 4.16 |
Earnings Yield |
— | — | — | — | — | — | — | — | 16.05% |
Free Cash Flow Yield |
— | — | — | — | — | — | — | — | 21.45% |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.23 |
Operating CF per Share |
(0.07) | (4.19) | (11.89) | (1.58) | (2.77) | (2.34) | (1.52) | (1.13) | 0.52 |
Capex per Share |
0.00 | (0.04) | (0.01) | 0.00 | (0.07) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.07) | (4.22) | (11.90) | (1.59) | (2.84) | (2.35) | (1.52) | (1.13) | 0.52 |
Cash per Share |
0.22 | 25.59 | 74.50 | 9.57 | 5.80 | 3.38 | 2.99 | 1.79 | 2.26 |
Shareholders Equity per Share |
(0.19) | (7.70) | (22.72) | 9.35 | 5.41 | 3.18 | 2.66 | 1.51 | 1.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.19) | (7.70) | (22.72) | 9.35 | 5.41 | 3.18 | 2.66 | 1.51 | 1.97 |
Free Cash Flow |
(2.35) | (8.53) | (24.69) | (52.29) | (102.86) | (85.26) | (66.65) | (62.21) | 29.64 |
Working Capital |
5.68 | 49.11 | 150.85 | 305.34 | 192.06 | 112.45 | 114.39 | 80.60 | 116.71 |
Capital Expenditures |
(0.08) | (0.08) | (0.02) | (0.14) | (2.71) | (0.18) | 0.06 | 0.09 | 0.03 |
Net Current Asset Value |
(6.78) | (15.68) | (49.74) | 297.64 | 163.92 | 87.15 | 92.20 | 61.82 | 101.64 |
EV/EBIT |
— | — | — | — | — | — | — | — | 0.76 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | — | — | 11.04 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.24 | 0.33 | 0.29 | 0.14 | 0.07 | 0.20 | 0.25 | 0.25 | 0.89 |
Cash ROIC |
(17.21%) | (23.62%) | (22.97%) | (8.40%) | (25.35%) | (35.75%) | (26.86%) | (34.21%) | 12.31% |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | — | 0.00 |
Accounts Payable Turnover |
0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
2,311.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
0.28 | 0.28 | 1.19 | 2.25 | 3.32 | 2.99 | 2.10 | 3.17 | 2.29 |
Average Assets |
29.92 | 25.91 | 105.06 | 243.98 | 288.68 | 201.97 | 157.41 | 140.60 | 132.83 |
Average Common Equity |
(11.11) | (11.11) | (31.35) | 130.30 | 251.83 | 155.80 | 116.22 | 100.01 | 97.75 |
Columns are period end dates